RefleXion, Telix Partner to Improve Treatment for High-risk or Recurrent Prostate and Aggressive Kidney Cancers

By News Release

 

RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, and Telix Pharmaceuticals Limited, a radiopharmaceutical company developing molecularly-targeted radiation (MTR) products, have announced a strategic collaboration to investigate the clinical utility of combining the companies’ technologies to improve treatment for high-risk or recurrent prostate and aggressive kidney cancers.

Under the agreement, the parties will evaluate several new positron emission tomography (PET) tracers, including 68Ga-PSMA-11 for prostate cancer and 89Zr-Girentuximab for kidney cancer1, to evaluate their potential in guiding BgRT to treat disease.

“The Telix tracers show considerable potential for detecting metastatic disease,” said Phuoc Tran, M.D., Ph.D., professor of radiation oncology and molecular radiation sciences, oncology and urology at the Johns Hopkins School of Medicine. “Combining them with RefleXion’s BgRT, which is designed to treat metastatic disease, could bring us a step closer to improving outcomes for these cancer types.”

BgRT uses biological emissions from a patient’s cancer cells created by injecting a small amount of a targeting molecule carrying a positron-emitting radioisotope known as a PET tracer to guide external-beam radiotherapy (EBRT). As the PET tracer binds to the tumor cells, it produces emissions that signal the cancer’s location. The RefleXion™ X1 machine detects these emissions using PET detectors and responds in real-time to direct BgRT to each tumor and destroy it, even in moving tumors. The most commonly used PET tracer is 18F-fluorodeoxyglucose (FDG), which can detect many different cancer types. However, its performance in certain tumor types and organs remains limited, particularly for kidney and prostate cancers. Telix’s new PET tracers are designed to target specific cancer types and are expected to be more accurate in this clinical setting.

“Telix’s cancer-specific PET tracers may provide a more complete and robust signal to guide BgRT for difficult-to-treat cancers of the prostate and kidney,” said Thorsten Melcher, Ph.D., chief business officer at RefleXion. “This collaboration is an important step in providing proof-of-concept that PET-based tumor emissions can guide our BgRT using different tracers and in different cancer types.”

Prostate specific membrane antigen (PSMA) imaging with 68Ga-PSMA-11 is suited for imaging high-risk or recurrent prostate cancer due to its ability to detect the spread of cancer outside the prostate bed. PSMA imaging is emerging as a potential new standard of care for detecting and staging prostate cancer, subject to approval by regulators2. For renal cancer applications, Telix’s 89Zr-Girentuximab, the first zirconium-labeled PET tracer in late-stage clinical development, targets carbonic anhydrase IX (CA9),  an antigen that may differentiate renal cancer, including metastases, from benign disease.

“The use of Telix’s cancer-specific PET tracers may enable us to guide RefleXion’s BgRT in patients with more advanced forms of prostate and kidney cancer,” said Christian Behrenbruch, Ph.D., CEO at Telix. “This collaboration also allows us to leverage the investment we’ve made in these tracers by expanding both their indications and overall procedure volumes.”

Back To Top

RefleXion, Telix Partner to Improve Treatment for High-risk or Recurrent Prostate and Aggressive Kidney Cancers.  Appl Rad Oncol. 

By News Release| July 09, 2020

About the Author

News Release

News Release

 


Copyright © Anderson Publishing, Ltd

 2020
    Agility CMS